Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Giovanni CrisafulliAndrea Sartore-BianchiLuca LazzariFilippo PietrantonioAlessio AmatuMarco MacagnoLudovic BaraultAndrea CassingenaAlice BartoliniPaolo LuraghiGianluca MauriPaolo BattuelloNicola PersoneniMaria Giulia ZampinoValeria PesseiPietro Paolo VitielloFederica TosiLaura IdottaFederica MoranoEmanuele ValtortaEmanuela BonoldiGiovanni GermanoFederica Di NicolantonioSilvia MarsoniSalvatore SienaAlberto BardelliPublished in: Cancer discovery (2022)
MMR-proficient mCRCs are unresponsive to immunotherapy. We provide the proof of concept that inactivation of MMR genes can be achieved pharmacologically with TMZ and molecularly monitored in the tissue and blood of patients with mCRC. This strategy deserves additional evaluation in mCRC patients whose tumors are no longer responsive to standard-of-care treatments. See related commentary by Willis and Overman, p. 1612. This article is highlighted in the In This Issue feature, p. 1599.